inTEST Corporation (INTT) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2024. inTEST Corporation is a global supplier of test and process technology solutions operating in three segments: Electronic Test, Environmental Technologies, and Process Technologies. The company serves markets including automotive, defense/aerospace, industrial, life sciences, security, and semiconductor. A significant event during the period was the acquisition of Alfamation S.p.A. on March 12, 2024, for approximately $21.9 million, which expanded the company's presence in the automotive and life sciences sectors.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $30.3 million | $30.9 million | $94.1 million | $95.4 million |
| Gross Profit | $14.0 million | $14.4 million | $40.9 million | $44.5 million |
| Gross Margin | 46.3% | 46.7% | 43.5% | 46.7% |
| Operating Income | $0.5 million | $2.5 million | $1.3 million | $9.3 million |
| Net Earnings | $0.5 million | $2.3 million | $1.4 million | $7.9 million |
| Diluted EPS | $0.04 | $0.19 | $0.11 | $0.68 |
| Cash & Equivalents | $18.0 million | $45.3 million (Dec 2023) | N/A | |
| Working Capital | $45.3 million | $61.5 million (Dec 2023) | N/A | |
| Total Debt | $16.1 million | $12.0 million (Dec 2023) | N/A |
Note: Debt includes Term Note, assumed Alfamation debt, and current portions. Cash decreased significantly due to the Alfamation acquisition.
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased 2.2% in Q3 and 1.4% for the nine months ended September 30, 2024, compared to the prior year. This was driven by a significant decline in the semiconductor market (down 38.2% in Q3 and 33.6% for 9M), partially offset by growth in the Automotive/EV market (up 252.1% in Q3 and 254.1% for 9M) and revenue from the Alfamation acquisition.
- Profitability Compression: Net earnings dropped significantly (78% in Q3, 82% for 9M) due to increased operating expenses associated with the Alfamation acquisition, higher amortization of acquired intangible assets, and lower gross margins.
- Balance Sheet Impact: Cash and cash equivalents declined from $45.3 million to $18.0 million, primarily due to the $18.7 million net cash paid for the Alfamation acquisition. Total assets increased to $158.4 million, driven by goodwill and intangible assets from the acquisition.
- Orders and Backlog: Orders increased 4.5% in Q3 to $28.1 million, driven by Alfamation and defense/aerospace growth. Backlog stood at approximately $45.5 million as of September 30, 2024.
Guidance, Outlook, and Risks
- Market Outlook: Management notes that the semiconductor market remains in a period of reduced demand, though there are indications of stabilization in the back-end semi market. The company continues to diversify into less cyclical markets (automotive, defense, life sciences) to reduce dependence on the semi market.
- Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024. Two material weaknesses were identified:
- Controls over the identification and application of U.S. GAAP for transactions involving discontinued material/components purchased on behalf of customers (contributed to prior restatements).
- Revenue recognition controls for Alfamation shipments where title transfers upon delivery (identified during Q2/Q3 integration).
- Supply Chain Risks: The company faces potential disruptions due to the Israel-Hamas conflict (sole-source capacitor supplier in Israel) and the Russia-Ukraine war (sole-source supplier in Belarus). The company maintains safety stock but is qualifying alternate suppliers.
- Liquidity: The company expects cash, cash equivalents, and the $10 million Revolving Credit Facility (currently undrawn) to be sufficient for short-term requirements. The Term Note capacity was expanded to $50.5 million with $30 million available.
Key Facts for Investor Verification
- Restatement History: Verify the impact of the restatement of Q3 2023 financials filed in March 2024 and the ongoing remediation of internal control material weaknesses.
- Acquisition Integration: Monitor the integration of Alfamation, specifically the realization of synergies and the impact of amortization on future earnings.
- Semiconductor Cycle: Assess the duration of the downturn in the semiconductor market and the company's ability to offset this with growth in non-semiconductor markets.
- Supply Chain Resilience: Track progress in qualifying alternate suppliers for critical components sourced from Israel and Belarus.
- Debt Covenants: Confirm continued compliance with debt covenants (Debt/EBITDA max 3.0x, Fixed Charge Coverage min 1.25x) given the increased debt load from the acquisition.